|
Hello Anna,
On December 29, 2022, President Biden signed the Fiscal Year 2023 Omnibus, passing the Mainstreaming Addiction Treatment (MAT) and Medication Access and Training Expansion (MATE) Acts. These bills were passed to expand access to buprenorphine for the treatment of opioid use disorder, and normalize and enhance substance use care across healthcare settings.
According to SAMHSA and the DEA:
- The MAT Act, which removes the X waiver previously required to prescribe buprenorphine for opioid use disorder, is effective immediately
- The MATE Act, which requires providers renewing or obtaining their DEA license to complete a training about substance use disorders, becomes effective in June 2023
MACS is closely monitoring guidance from state and federal agencies, and compiling the latest information on our website. The resources on this page offer information about the Omnibus, the bills, and the implications for healthcare providers and programs.
|